Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657813 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00657813 is a Phase 1 study that was terminated before completion, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 3 participants.
The verdict
NCT00657813, a Phase 1 study, was terminated before completion, sponsored by Institute for Neurodegenerative Disorders.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-330, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged Alzheimer's (AD) subjects and healthy controls To perform blood metabolite characterization of 123-I MNI-330 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of 123-I MNI-330 as a single photon computed tomography (SPECT) brain imaging agent Evaluate the test/retest reproducibility of 123-I MNI-330 and SPECT in AD subjects and healthy controls
Interventions
- DRUG MNI-330 as a brain SPECT tracer of Beta-Amyloid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657813
The ClinicalTrials.gov registry entry for NCT00657813 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MNI-330 as a brain SPECT tracer of Beta-Amyloid is the first listed.
NCT00657813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657813 about?
NCT00657813 is a clinical study titled "Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition". The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-330, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged Alzheimer's (AD) subjects and healthy controls To ...
What is the current status of trial NCT00657813?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2008-03. Estimated completion is 2008-09-30.
What interventions are being tested in trial NCT00657813?
The interventions under investigation include: MNI-330 as a brain SPECT tracer of Beta-Amyloid (DRUG).
Who is sponsoring clinical trial NCT00657813?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.